Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-DOTA-RET-L7
- Development stage
- Preclinical
- Lead developer
- Central South University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]Ga-DOTA-RET-L7 is a preclinical, research-stage radiopharmaceutical developed as a positron emission tomography (PET) imaging agent. It consists of the RET-L7 peptide, which was discovered via phage display and selected for its high-affinity binding to the receptor tyrosine kinase RET, conjugated to the chelator DOTA and radiolabeled with gallium-68 (68Ga). RET is highly overexpressed in neuroendocrine prostate cancer (NEPC), an aggressive, treatment-resistant subtype that is frequently prostate-specific membrane antigen (PSMA)-low or PSMA-negative. In preclinical mouse xenograft models, [68Ga]Ga-DOTA-RET-L7 demonstrated high, specific tumor uptake in RET-positive NEPC tumors with rapid blood clearance and strong self-blockade. It forms a theranostic pair with its therapeutic partner, [177Lu]Lu-DOTA-RET-L7, offering a promising diagnostic and therapeutic approach for PSMA-negative prostate cancer.
- Other names
- 68Ga-DOTA-RET-L7Ga-68-DOTA-RET-L7Ga68-DOTA-RET-L7Ga 68-DOTA-RET-L7Gallium-68 DOTA-RET-L7Gallium68 DOTA-RET-L7Gallium 68 DOTA-RET-L7
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on [68Ga]Ga-DOTA-RET-L7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-DOTA-RET-L7.